Last reviewed 2026-06-01 · How we verify

chemotherapy(c-ATT)

Sun Yat-sen University · Phase 3 active Small molecule Under review

chemotherapy(c-ATT) is a Topoisomerase inhibitor Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Treatment of various cancers. Also known as: c-ATT.

C-ATT works by targeting and inhibiting the function of cancer cells.

Chemotherapy, specifically the CHOP regimen, is used to treat high-risk, previously untreated adults with T-cell Lymphoma. The CHOP regimen typically involves a combination of bleomycin sulfate and cisplatin, along with other medications, to target and eliminate cancer cells.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	chemotherapy(c-ATT)
Also known as	c-ATT
Sponsor	Sun Yat-sen University
Drug class	Topoisomerase inhibitor
Target	Topoisomerase II
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

C-ATT is a chemotherapy drug that interferes with the DNA replication process in cancer cells, ultimately leading to cell death. This is achieved through the inhibition of topoisomerase II, an enzyme essential for DNA replication. As a result, cancer cells are unable to divide and grow, leading to tumor shrinkage and reduced cancer progression.

Approved indications

Treatment of various cancers

Common side effects

Myelosuppression
Nausea and vomiting
Hair loss
Fatigue

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

chemotherapy(c-ATT) CI brief — competitive landscape report
chemotherapy(c-ATT) updates RSS · CI watch RSS
Sun Yat-sen University portfolio CI

Frequently asked questions about chemotherapy(c-ATT)

What is chemotherapy(c-ATT)?

chemotherapy(c-ATT) is a Topoisomerase inhibitor drug developed by Sun Yat-sen University, indicated for Treatment of various cancers.

How does chemotherapy(c-ATT) work?

C-ATT works by targeting and inhibiting the function of cancer cells.

What is chemotherapy(c-ATT) used for?

chemotherapy(c-ATT) is indicated for Treatment of various cancers.

Who makes chemotherapy(c-ATT)?

chemotherapy(c-ATT) is developed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).

Is chemotherapy(c-ATT) also known as anything else?

chemotherapy(c-ATT) is also known as c-ATT.

What drug class is chemotherapy(c-ATT) in?

chemotherapy(c-ATT) belongs to the Topoisomerase inhibitor class. See all Topoisomerase inhibitor drugs at /class/topoisomerase-inhibitor.

What development phase is chemotherapy(c-ATT) in?

chemotherapy(c-ATT) is in Phase 3.

What are the side effects of chemotherapy(c-ATT)?

Common side effects of chemotherapy(c-ATT) include Myelosuppression, Nausea and vomiting, Hair loss, Fatigue.

What does chemotherapy(c-ATT) target?

chemotherapy(c-ATT) targets Topoisomerase II and is a Topoisomerase inhibitor.

Drug class: All Topoisomerase inhibitor drugs
Target: All drugs targeting Topoisomerase II
Manufacturer: Sun Yat-sen University — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Treatment of various cancers
Also known as: c-ATT

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing